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ABSTRACT
This report presents updated time-to-event variables from a multicenter phase II trial of reduced-dose 90Y
ibritumomab tiuxetan in patients with relapsed or refractory low-grade, follicular, or transformed B-cell
non-Hodgkin’s lymphoma (NHL) and mild thrombocytopenia (platelet counts of 100 to 149 3 109
platelets/L). Patients received a single course of ibritumomab tiuxetan radioimmunotherapy, with 90Y ibritumomab tiuxetan administered at 0.3 mCi/kg (compared to a standard dose of 0.4 mCi/kg). In 30 patients, the overall response rate was 83%, with complete responses (confirmed [CR] and unconfirmed
[CRu]) of 47%. Median follow-up time is currently 36.5 months (range: 7.5–54.9 months). Median duration of response was 11.5 months (range: 1.0–53.9 months), median time to progression was 9.4 months
(range: 1.7–54.81 months), and median time to next lymphoma therapy was 14.6 months (range:
2.3–54.91 months). Median overall survival time has not yet been reached. Long-term responses, defined
as time to progression of 12 months or greater, have been seen in 14 of 30 patients (47%) overall, and
12 of 14 CR/CRu patients (86%). Toxicities were primarily hematologic and reversible. No additional
long-term adverse events have been observed in the follow-up period, and treatment did not preclude subsequent lymphoma therapies.
Key words: ibritumomab tiuxetan, radioimmunotherapy, non-Hodgkin’s lymphoma, therapy, thrombocytopenia
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INTRODUCTION
The clinical course of low-grade or follicular Bcell non-Hodgkin’s lymphomas (NHL) is characterized by initial responsiveness to therapy and
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a continuous pattern of multiple remissions and
relapses. Patients usually receive several different lymphoma therapies over the course of their
disease. Persistent mild thrombocytopenia is seen
in a number of patients with relapsed or refractory NHL, and may be indicative of compromised
bone marrow reserve from prior therapy, lymphomatous bone marrow involvement, or both.
Patients with baseline thrombocytopenia are at
increased risk for chemotherapy-induced myelosuppression and its associated complications.1 As
such, the treatment of patients with low-grade or
follicular B-cell NHL and persistent mild thrombocytopenia presents a clinical challenge.
Radioimmunotherapy with ibritumomab tiuxetan is an effective treatment option for patients
with relapsed or refractory low-grade, follicular,
or transformed B-cell NHL.2–4 It was recognized
early in the clinical development of ibritumomab
tiuxetan that baseline platelet count, an indicator
of bone-marrow reserve, correlated with the risk
of hematologic toxicity. Early in the phase I/II
study, investigators noted that patients with baseline mild thrombocytopenia treated with 90Y ibritumomab tiuxetan at a dose of 0.4 mCi/kg were at
an increased risk of grade 4 hematologic toxicity,
compared to patients with normal baseline platelet
counts.2 Thereafter, patients with mild thrombocytopenia, defined as a baseline platelet count of
100 to 149 3 109 platelets/L, received a reduced
dose of 90Y-ibritumomab tiuxetan of 0.3 mCi/kg.
Subsequently, a phase II trial was conducted to
evaluate the safety and efficacy of reduced-dose
90Y ibritumomab tiuxetan radioimmunotherapy
in 30 patients with relapsed or refractory lowgrade, follicular, or transformed B-cell NHL and
mild thrombocytopenia (platelet counts of 100 to
149 3 109 platelets/L). Results from this study
were first reported in 2002.5 Patients received a
single course of treatment, in which 90Y ibritumomab tiuxetan was administered at a dose of
0.3 mCi/kg. The overall response rate was 83%
using International Workshop response criteria.6
Toxicities were primarily hematologic, and were
transient and reversible. This report provides updated data on response and survival outcomes
from an additional 2 years of follow-up time.

METHODS
A detailed description of the design and methods
of this single-arm, multicenter phase II study has
been previously reported.5 Briefly, patients age

18 or above with histologically confirmed relapsed
or refractory low-grade, follicular, or transformed
CD201 NHL and mild thrombocytopenia, defined
as a baseline platelet count 100 to 149 3 109
platelets/L were eligible for enrollment. Patients
had to have bidimensionally measurable disease,
with at least 1 lesion measuring 2.0 cm or greater
in a single dimension. Additional eligibility criteria included less than 25% bone marrow involvement; baseline World Health Organization (WHO)
performance status of 0, 1, or 2; no prior myeloablative therapy; and no prior radioimmunotherapy or anti-CD20 therapy. Patients had to have otherwise adequate hematologic and hepatic function
and provide written, informed consent.
On day 1 of therapy, patients received an i.v.
infusion of rituximab 250 mg/m2 followed by an
imaging dose of 111In ibritumomab tiuxetan 5
mCi (185 MBq). Provided biodistribution was
adequate on gamma-camera images, approximately 1 week later patients received a second infusion of rituximab 250 mg/m2, followed by 90Y
ibritumomab tiuxetan 0.3 mCi/kg (11 MBq/kg),
up to a maximum dose of 32 mCi (1.2 GBq).
Statistical Design
The primary study endpoint was overall response
rate (ORR), with complete response (CR/CRu)
rate, partial response (PR) rate, time to progression (TTP), duration of response (DR), and time
to next NHL therapy (TTNT) evaluated as secondary endpoints. Response rates were determined using International Workshop NHL response criteria.6
Definitions for time-to-event variables were as
follows: TTP was the time interval between the
date of the first treatment infusion to the date of
progression or date of last known contact for censored patients; DR was the time interval between
the date of the first IWRC response and the date
of disease progression; TTNT was the time interval between the date of the first treatment infusion to the date of the first subsequent NHL
therapy; overall survival (OS) was the time interval between the date of the first treatment infusion to date of death or last cutoff date for censored patients. Median TTP, DR, TTNT, and OS
were estimated using the Kaplan-Meier method.7
RESULTS
The study enrolled a total of 30 patients between
May 1998 and August 1999, with a current fol479
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low-up through August 2003, for a median follow-up time of 36.5 months (range: 7.5–54.81
months). All 30 patients enrolled were evaluable
for response and toxicity. Baseline patient characteristics are listed in Table 1. Patients had received a median of 2 prior therapies for NHL
(range: 1–9). Nineteen (19) patients (63%) were
resistant to at least 1 prior chemotherapy, and 14
patients (47%) were resistant to their last chemotherapy. Resistance was defined as a failure to
achieve a complete or partial response, or disease
progression, within 6 months.
Overall, 25 of 30 patients (83%) responded to
therapy, with 11 CR (37%), 3 CRu (10%) and 11
PR (37%) by International Workshop response
criteria.6 The median duration of response was
11.5 months (range: 1.0–53.9 months). The median time to progression for all patients was 9.4
months (range: 1.7–54.81 months) (Fig. 1).
Overall, responses have been durable. Long-term
responses, defined as time to progression of 12
months or greater, has been seen in 14 of 30 patients (47%) overall, including 12 of 14 patients
(86%) who achieved a CR or CRu (the 2 patients

Table 1. Patient Characteristics
Characteristic
Sex
Male
Female
Median age (yrs.), range
Histology
Small lymphocytic lymphoma
Follicular
Transformed
Disease stage
I/II
III/IV
Degree of bone marrow involvement
0 to ,5%
5% to 20%
20% to ,25%
No. of extranodal disease sites
0 or 1
2 or more
Tumor size
,5 cm
5 to ,7 cm
7 to ,10 cm
10 cm or more
Splenomegaly
Median no. of prior chemotherapy
(range)
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No.

%

18
12
61 (29–85)

60
40

2
25
3

7
83
10

3
27

10
90

10
12
8

33
40
27

24
6

80
20

16
9
3
2
7
2 (1–9)

53
30
10
7
23

Progression Free (%)

5171_e11_p478-481

100
90
80
70
60
50
40
30
20
10
0

x

0

x
x
x
x

x
x
x
x
x
x
x
x

6

x
x
x

x
x

12

x C
x

18

x
x
x

24

x

x

30

x

C

36

42

C

48

54

60

TTP (Months)

Figure 1. Time to progression (n 5 30); median time to
progression 5 9.4 months.

who relapsed within 12 months were true CRs,
not CRus). Median TTP in the 14 patients achieving long-term responses of 12 months or greater
was 24.6 months (range: 12.1–54.81 months),
and median TTP in all CR/CRu patients (independent of CR/Cru duration) was 24.5 months
(range: 4.9–54.8 months). Two (2) patients had
long-term partial responses of 12.6 and 17.3
months, respectively. These 2 patients had a residual mass on computed tomography (CT) scan
that did not meet CRu criteria but was more likely
fibrosis/scar than viable tumor, accounting for the
long duration of response. Functional imaging
with positron emission tomography (PET) was
not done, but may have better defined these residual masses. Two (2) of the patients have remained in continuous, complete remission for 41
and 54.81 months, respectively, following ibritumomab tiuxetan radioimmunotherapy.
Median overall survival time has not yet been
reached (data not shown). Overall median TTNT
was 14.6 months (range: 2.3–54.81 months). A
total of 24 patients received treatment subsequent
to ibritumomab tiuxetan radioimmunotherapy,
including rituximab, chemotherapy, and other
therapies. In the 13 patients who received rituximab as their first NHL treatment following ibritumomab tiuxetan radioimmunotherapy, clinical
responses were observed in 6 patients, 3 patients
did not respond to therapy, and clinical outcome
was unknown in the remaining 4 patients.
At this time, 7 of 30 patients enrolled in this
study have died; 6 deaths were the result of disease progression, and 1 death was the result of
other causes. In the original report, 1 patient with
a history of chronic alkylator exposure developed
acute myelogenous leukemia 20 months after
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study entry. With longer follow-up, there have
been no additional cases of secondary malignancies or other long-term toxicities in this patient
cohort.

sponse and durable remissions. Therapy is generally well tolerated, and does not preclude the
use of other subsequent lymphoma therapies.
ACKNOWLEDGMENTS

DISCUSSION
In this phase II trial, 30 patients with relapsed or
refractory low-grade, follicular, or transformed
B-cell NHL and mild thrombocytopenia received
a single course of radioimmunotherapy, with 90Y
ibritumomab tiuxetan administered at a reduced
dose of 0.3 mCi/kg. Overall, 83% of patients responded to therapy, with 14 patients (47%)
achieving a CR or CRu. Responses have been
durable, with 14 of 30 patients overall, and 12 of
14 CR/CRu patients, having a time to disease progression in excess of 12 months. Median TTP for
all patients was 9.4 months, with a median TTNT
of 14.6 months. In the 14 patients with long-term
responses, median TTP was 24.6 months. At this
time, median overall survival time has not yet
been reached.
With respect to safety, toxicities were primarily hematologic, but were transient and reversible.5 With extended follow-up, no long-term
adverse effects were noted, consistent with data
previously indicating that treatment with ibritumomab tiuxetan radioimmunotherapy is not associated with an increased risk of secondary malignancies.8 Recent reports have indicated that
subsequent NHL therapies, such as chemotherapy, immunotherapy, and even high-dose therapy
with stem-cell or bone-marrow transplant, can be
safely administered to patients who have previously received 90Y ibritumomab tiuxetan radioimmunotherapy.9,10 In this study, 24 of 30 patients received one or more subsequent NHL
therapies.
CONCLUSION
Persistent mild thrombocytopenia in patients with
relapsed or refractory NHL is indicative of impaired bone-marrow reserves, either from prior
chemotherapy, lymphomatous bone marrow involvement, or both. For these patients, treatment
with reduced-dose 90Y ibritumomab tiuxetan is
an effective option, producing a high rate of re-
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